International Journal of Hematology-Oncology and Stem Cell Research 2018. 12(1):43-48.

Study of the Relationship between HPA-1 and HPA-5 Gene Polymorphisms and Refractory to Platelet Therapy and Recombinant Factor VII in Glanzmann Thrombasthenia Patients in Southeast of Iran
Majid Naderi, Manijeh Habibpour, Shaban Alizadeh, Zahra Kashani Khatib, Akbar Dorgalaleh, Mohammed Awal Issah, Fatemeh Naadali


Background: Glanzmann Thrombasthenia (GT) is a rare autosomal disease. HPA (Human Platelet Alloantigen) is a surface polymorphic alloantigen of platelets. This study was intended to investigate and compare the polymorphism of HPA-1 and HPA-5 genes in two groups of GT patients, with and without resistance to platelet and recombinant factor VII therapy.

Materials and Methods: This case control study was performed on GT patients (n=16) with resistance to platelet therapy and recombinant factor VII and control group of GT patients (n=16) without resistance to platelet therapy and recombinant factor VII. The consent form was completed by each patient. Gene polymorphisms of HPA-1 and HPA-5 were investigated using SSP-PCR, and the obtained data were analyzed using statistical software SPSS16.0.

Results: The results indicated no significant relationship between the studied genes and their resistance to platelet therapy and recombinant factor VII. The frequencies of HPA-1 genotype a/a were 98% and 94% in patient and control groups, respectively. The frequency of allele b was found to be less than allele a. The value of this allele was 4% in patient group and 1% in control group. In addition, the HPA-5a/a (98%) was the most frequent alloantigen?? (check it) in both groups. Seven percent (7%) of the patients had the HPA-5a/b genotype, and the HPA-5b/b was found to be absent in these individuals.

Conclusion: According to the results obtained, it could be concluded that these genes play no role in resistance to platelet therapy.



Human platelet Ag-1, Human platelet Ag-5, Platelet therapy, Glanzmann thrombastenia

Full Text:



Franchini M, Favaloro EJ, Lippi G. Glanzmann thrombasthenia: An update. Clin Chim Acta. 2010;411(1-2):1-6.

Bellucci S, Caen J. Molecular basis of Glanzmann’s Thrombasthenia and current strategies in treatment. Blood Rev. 2002;16(3):193-202.

Curtis, BR , McFarland JG. Human platelet antigens. 2013. Vox Sang. 2014;106(2):93-102.

Corral J, Rivera J, Gonzalez-Conejero R, et al. The number of platelet glycoprotein Ia molecules is associated with the genetically linked 807 C/T and HPA-5 polymorphisms. Transfusion. 1999. 39(4): 372-8.

Tan JY, Lian LH, Nadarajan VS. Genetic polymorphisms of human platelet antigens-1 to -6, and -15 in the Malaysian population. Blood Transfus. 2012 10(3):368-76.

Shaiegan M, Samiei S, Ataee Z, et al. Frequency of Human Platelet Antigens (HPA-2/3/5) Polymorphism in Iranians Evaluated by RFLP-PCR. IJBC; 2011;2(4):101-5.

Madani T, Samiee S, Attaei Z, et al . Platelet antigens frequency in blood donors: comparison of molecular detection with ELISA method (for HPA-1a) . SJIBTO. 2007; 4(3): 165-174.

Tanboğa İH, Can MM, Özkan A, et al. Relationship between human platelet antigen-1 gene polymorphism and clopidogrel resistance in patients with coronary artery disease.Turk Kardiyol Dern Ars. 2013;41(5):379-85.

Soundravally R, Hoti SL. Immunopathogenesis of dengue hemorrhagic fever and shock syndrome: Role of TAP and HPA gene polymorphism. Hum Immunol. 2007; 68(12):973-9.

Ferrer G, Muñiz-Diaz E, Aluja M, et al. Analysis of human platelet antigen systems in a Moroccan Berber populaion. Transfus Med. 2002;12(1):49-54.

Drzewek K, Brojer E, Zupanska B. The frequency of human platelet antigen (HPA) genotypes in the Polish population. Transfus Med. 1998;8(4):339-42.

Poon MC, Zotz R, Di Minno G, et al. Glanzmann’s thrombasthenia Treatment: A Prospective Observational Registry on the Use of Recombinant Human Activated factor VII and other hemostatic Agents. Semin Hematol.2006; 43(1 Suppl 1):S33-6.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.